Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chromadex (CDXC)
NASDAQ:CDXC
CDXC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.48 - $7.97
Previous CloseN/A
Volume55.16K
Average Volume (3M)349.48K
Market Cap
$451.43M
Enterprise Value$254.35M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)309.0
Beta1.20
Next Earnings
Mar 05, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding76,383,270
10 Day Avg. Volume372,774
30 Day Avg. Volume349,477
Standard Deviation0.36
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.92
Price to Cash Flow (P/CF)32.30
P/FCF Ratio32.30
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda130.70
Forecast
1Y Price Target
$7.40Price Target Upside29.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Chromadex News
PremiumCompany Announcements
ChromaDex Reports Strong Q3 2024 Financial Results
PremiumCompany Announcements
Chromadex Reports Strong Q3 2024 with 31% Sales Increase
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceChromaDex reported an improvement in adjusted EBITDA to $2.9M from $0.5M in the year-ago period, indicating better financial health.
Regulatory AchievementsChromaDex announced FDA Orphan Drug Designation and Rare Pediatric Disease Designation for nicotinamide riboside chloride.
Revenue GrowthChromaDex expects 15% revenue growth year-over-year, with potential upside from new partnerships, channels, and products.
Bears Say
Earnings PerformanceChromaDex reported a breakeven per share performance, beating the forecast of a net loss of $0.02 per share, which, while positive, may suggest challenges in achieving significant profitability.
Revenue ExpectationsThe company recorded $22.7M in top-line revenue, which is essentially in-line with the forecast of $23M, suggesting limited revenue surprise.
Sales And Marketing EfficiencySales and marketing expenses accounted for 27.5% of net sales, a reduction from 31% in the year-ago period, indicating tighter control over costs which may not translate into higher sales.
---
Ownership Overview
30.42% Insiders
6.88% Mutual Funds
7.61% Other Institutional Investors
48.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDXC FAQ
What was Chromadex’s price range in the past 12 months?
Chromadex lowest stock price was $1.48 and its highest was $7.97 in the past 12 months.
What is Chromadex’s market cap?
Chromadex’s market cap is $451.43M.
When is Chromadex’s upcoming earnings report date?
Chromadex’s upcoming earnings report date is Mar 05, 2025 which is in 12 days.
How were Chromadex’s earnings last quarter?
Chromadex released its earnings results on Oct 31, 2024. The company reported $0.029 earnings per share for the quarter, beating the consensus estimate of $0.006 by $0.023.
Is Chromadex overvalued?
According to Wall Street analysts Chromadex’s price is currently Undervalued.
Does Chromadex pay dividends?
Chromadex does not currently pay dividends.
What is Chromadex’s EPS estimate?
Chromadex’s EPS estimate is 0.02.
How many shares outstanding does Chromadex have?
Chromadex has 76,383,270 shares outstanding.
What happened to Chromadex’s price movement after its last earnings report?
Chromadex reported an EPS of $0.029 in its last earnings report, beating expectations of $0.006. Following the earnings report the stock price went up 67.908%.
Which hedge fund is a major shareholder of Chromadex?
Currently, no hedge funds are holding shares in CDXC
---
Chromadex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.40 (29.82% Upside)
$7.40 (29.82% Upside)
Blogger Sentiment
Bullish
CDXC Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $21.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
260.49%
12-Months-Change
Fundamentals
Return on Equity
4.82%
Trailing 12-Months
Asset Growth
5.68%
Trailing 12-Months
Company Description
Chromadex
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
---
CDXC Company Deck
---
CDXC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant positive financial performance, with record revenue and growth primarily driven by NIAGEN and e-commerce sales. The company also made strategic advancements with the NIAGEN+ product line and FDA communications. However, challenges in the Hong Kong market and increased legal expenses were noted as lowlights.Read More>---
CDXC Stock 12 Month Forecast
Average Price Target
$7.40
▲(29.82% Upside)
Technical Analysis
Best Analysts Covering CDXC
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+49.53%
reiterated a buy rating 3 months ago
Copying Sean McGowan's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +49.53% per trade.
---